PAM Inhibitor Approved for HR-Positive Breast Cancer
29/07/2026
Introducción The FDA approved the kinase inhibitor gedatolisib (Revtorpyk) for treating hormone receptor (HR)-positive/HER2-negative breast cancer in patients whose disease
Introducción The FDA approved the kinase inhibitor gedatolisib (Revtorpyk) for treating hormone receptor (HR)-positive/HER2-negative breast cancer in patients whose disease
Aspirin and Clot Prevention An aspirin-only approach to postoperative prophylaxis after arthroplasty was as effective and safe as upfront rivaroxaban
Daranersen and the CELIA Trial The tau-targeting agent diranersen did not meet the primary endpoint of the phase II CELIA
Children born during England’s COVID lockdown appeared to have markedly lower executive function than expected for their age, interim results
Clinical takeaway: Consider Cyclospora infection in patients with prolonged or relapsing watery diarrhea during the May–August cyclosporiasis season—even without international